ArticleMolecular cancer therapeutics2021
The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- CK1α agonists attenuate medulloblastoma stemness and relapse risk.Cell death & disease · 2026Article
- G-quadruplex stabilization via small molecules as a potential anti-cancer strategy.Cellular & molecular biology letters · 2026Review
- Review
- Beyond antiparasitic activity: elucidating the antibacterial potency of pyrvinium pamoate.Microbiology spectrum · 2025Article
- Quantitative Proteomics Unveils the Synergistic Effects of Combination Drugs on Cytoskeleton Composition and Autophagy-Mediated Cell Death in Neuroblastoma.Journal of proteome research · 2025Article
- Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker.International journal of molecular sciences · 2025Article
- Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma.The Journal of clinical investigation · 2025Article
- Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma.bioRxiv : the preprint server for biology · 2024Article
- Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti-Pancreatic Cancer Activity in 2D and 3D Cell Culture Models.Journal of cellular and molecular medicine · 2024Article
- Exploring the impact of mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 on breast cancer cell metabolism.BMC cancer · 2024Article
- Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- RNA-binding protein HuR reprograms immune T cells and promotes oral squamous cell carcinoma.Oral oncology reports · 2024Article
- In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin againstTropical medicine and infectious disease · 2024Article
- The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.Nature communications · 2023Article
- Targeting the RNA-Binding Protein HuR in Cancer.Cancer research · 2023Review
- Toxic Effects of Penetrating Cations.Membranes · 2023Review
- Article
- Metabolic modulation of mitochondrial mass during CD4Cell chemical biology · 2023Article
- Application of G-quadruplex targets in gastrointestinal cancers: Advancements, challenges and prospects.World journal of gastrointestinal oncology · 2023Review
- Current trends and future prospects of drug repositioning in gastrointestinal oncology.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 12 institutions in 2 countries.
Christopher W Schultz *The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-5731-2847
Grace A McCarthy *Brenden-Colson Center for Pancreatic Care, Departments of Surgery and Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Teena Nerwal *The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Avinoam NevlerThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-5928-0559
James B DuHadawayThe Lankenau Institute of Medical Research, Wynnewood, Pennsylvania.ORCID 0000-0001-8136-1999
Matthew D McCoyGeorgetown University, Washington, District of Columbia.ORCID 0000-0001-7601-6963
Wei JiangPathology Department, Thomas Jefferson University, Philadelphia, Pennsylvania.
Samantha Z BrownBrenden-Colson Center for Pancreatic Care, Departments of Surgery and Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0002-6506-246X
Austin GoetzThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Aditi JainThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Valerie S CalvertGeorge Mason University, Fairfax, Pennsylvania.
Vikalp VishwakarmaThe University of Kansas, Lawrence, Kansas.ORCID 0000-0001-5555-2126
Dezhen WangEppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska.
Ranjan PreetThe University of Kansas, Lawrence, Kansas.
Joel CasselWistar Institute, Philadelphia, Pennsylvania.
Ross SummerJane and Leonard Korman Respiratory Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.
Hoora ShaghaghiJane and Leonard Korman Respiratory Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.
Yves PommierDevelopmental Therapeutics Branch, NCI Bethesda, Maryland.
Simone A BaechlerDevelopmental Therapeutics Branch, NCI Bethesda, Maryland.
Michael J PishvaianJohns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-1165-9041
Talia GolanOncology institute, Chaim Sheba Medical Center, Tel Aviv, Israel.
Charles J YeoThe Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
Emanuel F PetricoinGeorge Mason University, Fairfax, Pennsylvania.
George C PrendergastThe Lankenau Institute of Medical Research, Wynnewood, Pennsylvania.ORCID 0000-0002-1449-7332
Joseph SalvinoWistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-2184-5980
Pankaj K SinghEppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska.
Dan A DixonThe University of Kansas, Lawrence, Kansas.ORCID 0000-0001-5631-4365
Jonathan R BrodyBrenden-Colson Center for Pancreatic Care, Departments of Surgery and Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon. brodyj@ohsu.edu.
Thomas Jefferson University · USOregon Health & Science University · USUniversity of Kansas · USGeorge Mason University · USLankenau Institute for Medical Research · USNebraska Medical Center · USNeuroDevelopment Center · USRothman Institute · USThe Wistar Institute · USGeorgetown University · USTel Aviv University · ILUniversity of Baltimore · US
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MUnderstanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5MTissue CoreP50CA127297 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI HOLLINGSWORTH, MICHAEL A. · 2008 to 2018
$17.1MCLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM008562 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WALTER K KRAFT, Scott A. Waldman · 1995 to 2026
$10.2MProject 3: MUC16-Mediated Metabolic Reprograming Induces PC MetastasisP01CA217798 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2018 to 2022
$8.1MTargeting Tumor-Stromal Metabolic Cross-Talk in Pancreatic CancerR01CA163649 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Pankaj Kumar Singh · 2012 to 2026
$5.4MMitochondrial calcium signaling in pancreatic cancer metastasis and progressionR01CA256911 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Pankaj Kumar Singh, Shengyu Yang · 2022 to 2026
$3.2MNano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted TherapyR01CA243445 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI DIXON, DAN ALAN, XU, LIANG · 2019 to 2023
$3.0MComparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9MMetabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic CancerR01CA216853 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SINGH, PANKAJ KUMAR · 2017 to 2021
$2.6MTargeting HuR to improve a synthetic lethal therapy for pancreatic cancerR01CA212600 · NCI · THOMAS JEFFERSON UNIVERSITY · PI BRODY, JONATHAN · 2017 to 2021
$1.9MIntramural NIH HHS Z01 BC006150NCI NIH HHS P01 CA217798NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA056036NCI NIH HHS P30 CA069533NCI NIH HHS P50 CA127297NCI NIH HHS R01 CA163649NCI NIH HHS R01 CA212600NCI NIH HHS R01 CA216853NCI NIH HHS R01 CA243445NCI NIH HHS R01 CA256911NCI NIH HHS U01 CA224012NIGMS NIH HHS T32 GM008562
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal aggressive cancer, in part due to elements of the microenvironment (hypoxia, hypoglycemia) that cause metabolic network alterations. The FDA-approved antihelminthic pyrvinium pamoate (PP) has previously been shown to cause PDAC cell death, although the mechanism has not been fully determined. We demonstrated that PP effectively inhibited PDAC cell viability with nanomolar IC50 values (9-93 nmol/L) against a panel of PDAC, patient-derived, and murine organoid cell lines.
Indexed as
AdenocarcinomaAnimalsAnthelminticsCarcinoma, Pancreatic DuctalHumansMetabolomicsMicePyrvinium CompoundsSurvival AnalysisUnited StatesUnited States Food and Drug AdministrationAnthelminticspyrviniumPyrvinium Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.